





## **Driving Research Beyond**

Home About Galileo Contract Research Pipeline Partners Business Media

## Partners

Advisor

Grants

## **Partners**

Galileo Research is seeking a partner to raise funding for Phase II and Phase III development for TALL-104 program in ovarian cancer.

Ovarian cancer is the second most common gynecological malignancy among women. Among the seven major markets, it has affected around 170,000 women in 2010, with the UK having the highest prevalence among the top five EU countries.

The prevalence of ovarian cancer is set to grow from 170,280 in 2010 to 174,429 in 2016. Approximately 70% of the patients with ovarian cancer are diagnosed with advanced disease. The standard treatment includes surgery, followed by a combination of platinum and taxane adjuvant chemotherapy.

Home Page About Galileo Research News Contacts Privacy Policy Cookie Policy Site Map Credit

GALILEO RESEARCH s.r.I. Sede Legale: Via del Paradiso, 6 - 56019 - Vecchiano Loc. Migliarino Pisano - Phone +39.050.31.54.283 - Fax +39.050.80.33.38

Fiscal Code and Pisa Trade Number 1855640502 - REA Pisa № 160639/2011 - Partita IVA 01855640502 Capital Stock € 100.000 fully paid in

Company subject to management and coordination by MDM HOLDING S.p.A. Pisa (Fiscal ID 01410690505)